MedTrace Logo

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385678 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-09-19

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.

Conditions

  • Advanced KRAS G12D Mutant Solid Tumors

Interventions

DRUG

HRS-4642

administrated per dose level in which the patients are assigned

DRUG

Adebrelimab

administrated per dose level in which the patients are assigned

DRUG

SHR-9839

administrated per dose level in which the patients are assigned

DRUG

Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection

administered as prescribed by the investigator.

DRUG

Cetuximab Solution for Infusion

administrated per dose level in which the patients are assigned

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-05
Primary Completion
2025-12-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06385678 on ClinicalTrials.gov